Mr. Craig Schneider reports

INMED EXPANDS BOARD OF DIRECTORS WITH SENIOR LIFE SCIENCE AND FINANCIAL EXECUTIVES; APPOINTS TAREK S. MANSOUR, PH.D., AND KEVIN PUIL TO BOARD OF DIRECTORS

Tarek Mansour, PhD, a veteran executive in the life science sector, and Kevin Puil, an experienced investment manager, have joined InMed Pharmaceuticals Inc.'s board of directors. Dr. Mansour has more than 26 years of experience in drug discovery and development, and has held senior leadership and management positions at leading biotechnology and pharmaceutical companies. Mr. Puil is an analyst and former hedge fund manager with 20 years experience managing investments. These strategic additions add significant expertise and insight to InMed, as the company advances its clinical-stage pipeline of novel therapies.

"We are pleased to welcome Dr. Mansour and Mr. Puil to our board of directors," said Craig Schneider, president and chief executive officer. "Dr. Mansour is a distinguished R&D [research and development] executive and entrepreneur, whose experience and expertise in both biotechnology and pharmaceutical drug development will be instrumental in guiding our strategic initiatives. As we continue along our accelerated growth trajectory, Mr. Puil's expertise in finance and investments significantly strengthens InMed's infrastructure. We look forward to leveraging their collective insight as we move forward."

Dr. Mansour was previously with Xenon Pharmaceuticals as its executive vice-president. He also held similar positions at Pfizer and Wyeth Pharmaceuticals, prior to founding Sabila Biosciences LLC, where he is currently the chief executive officer.

Dr. Mansour's expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evaluation including Food and Drug Administration approvals, and late-stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.

Dr. Mansour received a bachelor of science degree in chemistry from the American University of Beirut, Lebanon (1977), a master of science in chemistry from the University of Manchester Institute of Science and Technology, United Kingdom (1979), a PhD degree from the University of Missouri-Columbia, United States (1982), and a diploma in applied management from McGill University, Canada (1993). Following postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research associate in the immunomedicinal chemistry chair.

Mr. Puil is currently a managing partner at a private equity fund based in California. Prior to that, he held senior positions at several firms including Bolder Investment Partners in Vancouver (now Haywood Securities), where he was a partner and portfolio manager; and in San Francisco at Gissen & Associates as portfolio manager, and the Encompass Fund as senior analyst. He currently serves as a board director of two Toronto Stock Exchange companies. He holds a degree in economics from the University of Victoria in British Columbia and is a chartered financial analyst charterholder.

We seek Safe Harbor.